Breast cancer 5 year survival rates (UK, 1975) by stage at diagnosis

5-year survival in breast cancer (Europe; 1990) Switzerland Finland France Italy Netherlands Germany Denmark England Spain Scotland Estonia Poland Five-year survival (%) J Nat Cancer Inst 1995; 87: year survival (%) No. of patients ,24311,1232,4983,5952,6533,35917,49860,3901,04311,2612,3871,089

Breast cancer demographics Anderson WF et al. Breast Cancer Res Treat 2002; 76: 27– ER-positive ER-negative Proportion of patients (%) Mean age (years) Age at diagnosis (%) <50  50 Tumour size (%) >2.0 cm  2.0 cm unknown Patients (n=82,488) ER = oestrogen receptor

Placebo Tamoxifen Breast cancer continuum: consistency of results on 5 years of tamoxifen

Breast cancer incidence and mortality England France Germany Total EU USA n 10,846 10,811 17,692 73,592 39,800 n 34,176 35,726 48, , ,300 Incidence Mortality Jemal A et al. CA Cancer J Clin 2003; 53: 5–26; Cancer Research UK. Cancer Stats – Incidence & Mortality UK, April 2003; Ferlay et al. IARC Press, 1999

Changes in incidence and mortality from breast cancer (UK, 1994) Incidence In the UK in 1992, the incidence of breast cancer was 40% higher than in 1979 Incidence of breast cancer in the UK (age 50–64) increased steeply following the introduction of screening in 1988 Mortality Year Screening introduced Age-standardised mortality from breast cancer in women aged 55-69, England and Wales, Quinn M, et al. Br Med J 1995; 311:

Improved Outlook in Early Breast Cancer: Indirect Comparison of ATAC data with EBCTCG 1995 Overview 1 (Hormone Receptor +ve Patients >50 Years) Estimated percentage still without recurrence as first event years % 70.5% 3-year event-free rate: 90% 92% *ATAC data truncated at 42 months 1 EBCTCG. The Lancet 1998; 351: 1451–1467 Anastrozole (ATAC data) Tamoxifen (ATAC data) Tamoxifen (EBCTCG overview) Control (EBCTCG overview)

Cancer Research UK, 2003 Number of new cases Age at diagnosis Rate per 100,000 population number rates Number of new breast cancer cases diagnosed and age-specific rates per 100,000 population, UK, 1999

Survival from time of tumour recurrence: in all patients with advanced breast cancer

Survival in advanced breast cancer Year of 1st recurrence Median Survival (months) 3 year OS (%) 5 year OS (%)